Matthew W. Foehr
2021 - Ligand Pharmaceuticals
In 2021, Matthew W. Foehr earned a total compensation of $5.3M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 52% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $259,467 |
|---|---|
| Option Awards | $1,226,357 |
| Salary | $518,933 |
| Stock Awards | $3,146,844 |
| Other | $130,603 |
| Total | $5,282,204 |
Foehr received $3.1M in stock awards, accounting for 60% of the total pay in 2021.
Foehr also received $259.5K in non-equity incentive plan, $1.2M in option awards, $518.9K in salary and $130.6K in other compensation.
Rankings
In 2021, Matthew W. Foehr's compensation ranked 2,451st out of 12,406 executives tracked by ExecPay. In other words, Foehr earned more than 80.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,451 out of 12,406 | 80th |
Division Manufacturing | 972 out of 5,494 | 82nd |
Major group Chemicals And Allied Products | 372 out of 2,369 | 84th |
Industry group Drugs | 324 out of 2,090 | 85th |
Industry Pharmaceutical Preparations | 213 out of 1,537 | 86th |
Source: SEC filing on April 22, 2022.
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2021.